about

Creating Value Through Innovation and Focus

Our pipeline represents years of focused research. We're advancing breakthrough therapies across multiple modalities. Each program targets critical unmet medical needs with precision.

Explore Programs
Portfolio Overview

Pipeline Overview Table

Our development portfolio spans discovery through late-stage clinical programs. We track key milestones and value inflection points across all assets.

Small Molecules

Lead Programs: Small Molecule Therapeutics

HECIT-0159: Transforming Wound healing

Our wound healing program has advanced a novel topical therapeutic molecule through successful in vivo animal studies, demonstrating robust efficacy, safety, and translational relevance. The molecule is designed to accelerate tissue repair, modulate inflammation, and support regenerative healing, addressing a significant unmet need in chronic and diabetic wound care. With reproducible preclinical data, a scalable formulation strategy, and a clear regulatory and manufacturing pathway, the program is positioned for late-stage preclinical development and near-term commercialization through licensing, co-development, or market entry partnerships.

Science

How Our Candidates Work

Small Molecule Approach

Our compounds modulate key signaling pathways. They restore cellular balance without complete pathway shutdown.

  • Target kinases regulating inflammation
  • Reversible binding allows physiologic control
  • Cross blood-brain barrier when needed
  • Predictable pharmacokinetics enable dosing optimization

Peptide Strategy

Designer peptides mimic or block natural ligands. Precision targeting minimizes off-target effects significantly.

  • Receptor-specific binding achieves selectivity
  • Conformational stability resists degradation
  • Subcutaneous delivery sustains therapeutic levels
  • Biodegradable components ensure safety
1

Target Engagement

Drug binds specific receptor or enzyme with high affinity and selectivity.

2

Signal Modulation

Pathway activity adjusts to therapeutic range, correcting disease state imbalance.

3

Clinical Benefit

Downstream effects reduce symptoms, slow progression, and improve patient outcomes.

Competitive Positioning: Differentiators

We've engineered distinct advantages across our portfolio. Each program addresses gaps left by existing therapies through innovation.

Novel Mechanisms

Our targets represent pathways untouched by current standard-of-care. First-in-class potential across three programs creates market leadership opportunity.

Superior Profiles

Preclinical data demonstrates improved safety and efficacy versus benchmarks. Pharmacokinetic advantages enable better dosing regimens.

Strategic Partnerships

Collaborations with academic centers and industry leaders validate our science. Shared resources accelerate development timelines significantly.

IP Protection

Robust patent estates cover composition, formulation, and methods. Exclusivity for all
the clinical assets.

Pipeline in Motion

Our development engine transforms scientific insight into therapeutic reality. Progress unfolds across parallel tracks toward commercial milestones.

1

Discovery

Target identification and validation. Lead compound optimization through iterative chemistry.

2

Preclinical

Safety and efficacy testing in disease models. Manufacturing scale-up begins.

3

Clinical Development

Phase 1/2/3 trials establish safety and efficacy. Regulatory engagement throughout.

4

Regulatory Review

NDA/BLA submission and approval. Market access planning and launch preparation.

5

Commercial Success

Patient access expands globally. Post-marketing studies extend indications and value.

Patient Impact Potential

Before treatment, patients experience debilitating symptoms limiting daily function. Current options provide incomplete relief with burdensome administration.

After our therapies, disease control improves significantly. Quality of life metrics show meaningful gains. Convenient dosing enhances long-term adherence.

Market Transformation

Our entry disrupts stagnant treatment paradigms. Physicians gain powerful new tools addressing unmet needs. Payers benefit from improved outcomes and cost-effectiveness.

First-mover advantage establishes market leadership. Follow-on indications expand addressable populations. Platform potential enables future pipeline expansion.